MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, effective November 17, 2023, $2,965,000 of Secured Convertible Debentures were fully redeemed pursuant to exercise of the Conversion Rights by the Holders, resulting issuance of 59,300,000 common shares and 59,300,000 share purchase warrants exercisable at $0.20 until December 31, 2027.
“This conversion of this Secured Debt sends a strong message of confidence in the future of MedX and continued support by the former debt-holders, and has eliminated of all the secured debt from the Company’s Balance Sheet. This positive step will greatly help the Company move forward with the ongoing roll-out of its SIAscopy® on DermSecure® telemedicine platform,” said Stephen Lockyer, CEO of MedX.
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121594232/en/